pCDCAR1 BCMA h(BBζ) (CAR-ZP004)

CAR Construction : JCARH125 scFv-BBζ

Fig.1 Representative dot plots depicting anti-BCMA CAR expression on live CD3+ T cells by FACS after 14 days of anti-BCMA CAR T-cell production.

UT cells were generated from the same donor.

Metelo, A. M., Jozwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., ... & Benjamin, R. (2022). Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors. Cancer Research Communications, 2(3), 158-171.

CAR Construction : JCARH125 scFv-BBζ

Fig.2 Representative histograms comparing the expression of the T-cell checkpoint inhibitory molecules TIGIT, PD-1.

Multiple myeloma (MM)-derived (red) anti-BCMA CAR T cells, analyzed by FACS at the end of production (day 14, before cryopreservation).

Metelo, A. M., Jozwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., ... & Benjamin, R. (2022). Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors. Cancer Research Communications, 2(3), 158-171.

CAR Construction : JCARH125 scFv-BBζ

Fig.3 Specific anti-BCMA CAR T-cell killing (%) against different BM samples (n = 12) after the ex vivo CTL assay at 10:1 E/T ratio.

The anti-BCMA CAR T-cell killing percentage was quantified as: [(%multiple myeloma cell lysis cocultured with anti-BCMA CAR T cells − % multiple myeloma cell lysis cocultured with UT cells) / % spontaneous multiple myeloma cell lysis].

Metelo, A. M., Jozwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., ... & Benjamin, R. (2022). Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors. Cancer Research Communications, 2(3), 158-171.

CAR Construction : JCARH125 scFv-BBζ

Fig.4 Anti-BCMA CAR T-cell activity can be enhanced by increasing BCMA levels on the multiple myeloma (MM) cell surface.

Histograms showing the BCMA expression of multiple myeloma primary cells from each BM sample.

Metelo, A. M., Jozwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., ... & Benjamin, R. (2022). Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors. Cancer Research Communications, 2(3), 158-171.

CAR Construction : JCARH125 scFv-BBζ

Fig.5 Specific killing of MM48, MM52, and MM57 cancer cells by anti-BCMA CAR T cells or UT cells, with and without GSI treatment.

Statistical analysis was performed using one-tailed paired t test.

Metelo, A. M., Jozwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., ... & Benjamin, R. (2022). Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors. Cancer Research Communications, 2(3), 158-171.